ArticleArchives of endocrinology and metabolism2026
Mild and non-persistent fasting plasma glucose elevation in the first trimester of pregnancy is not associated with increased risk of gestational diabetes mellitus and adverse pregnancy outcomes.
Article in Archives of endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate pregnancy outcomes in women with early gestational diabetes mellitus (eGDM) diagnosed by mild elevation of fasting plasma glucose (FPG) in the first trimester. SUBJECTS AND
methodsThis prospective cohort study included 114 pregnant women with first trimester FPG <100 mg/dL (5.6 mmol/L). Women with FPG ≥92 mg/dL (5.1 mmol/L) and <100 mg/dL (5.6 mmol/L) were classified as having eGDM, and FPG was reassessed after approximately 3-4 weeks. Women whose repeated FPG was <92 mg/dL (5.1 mmol/L) were assigned to Group 1 (G1; n = 33) and did not receive eGDM treatment. These participants underwent an oral glucose tolerance test (OGTT) between 24-28 weeks of gestation and, depending on the results, initiated treatment as indicated. Women with eGDM and a second FPG 92-125 mg/dL (5.1-6.9 mmol/L) were assigned to Group 2 (G2; n = 31) and immediately started eGDM treatment. The control group (G3; n = 50) was composed by pregnant women with FPG <92 mg/dL (5.1 mmol/L) in the first trimester.
resultsG1 and G3 had lower pre-pregnancy body mass index, less chronic hypertension, lower rates of GDM history, and lower multiparity compared to G2. There was no significant difference in GDM diagnosis by OGTT between G1 and G3 (27.3% vs. 20.0%, p = 0.594). G3 gained more weight (10.2 ± 7.6 kg, 7.5 ± 6.4 kg, and 13.5 ± 6.1 kg for G1, G2, and G3, respectively; p = 0.001). Other outcomes between G1 and G3 were similar.
conclusionWomen with eGDM diagnosed by mild, non-persistent FPG elevation in the first trimester had similar outcomes to those with normal early FPG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.